VictorY, an Amsterdam, The Netherlands-based biotechnology company, raised €31M in seed funding.
The round was led by Forbion and an unnamed global investment firm, with participation from BGV and Eli Lilly and Company.
The company intends to use the funds to establish pre-clinical proof of concept for vectorized antibodies in target indications of ALS and Alzheimer’s, to further expand the team, and to establish proprietary manufacturing capabilities, including a GMP facility in the Netherlands.
Led by newly appointed CEO Alexander Vos and CTO Dr. Sander van Deventer, VectorY Therapeutics is a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies.
Launched in October 2020, the company has established its laboratories and offices at the Amsterdam Science Park in The Netherlands and is developing a pipeline of vectorized antibodies targeting muscular and CNS diseases, based on a novel AAV platform and innovative antibody-based targeted degradation technologies. These non-immunogenic viral vectors have enhanced properties of cell type specificity, thus improving delivery, durability and accessibility of targeted tissues and cells.
The company’s Board of Directors will continue to be chaired by Dr. Carlo Incerti, previously Chief Medical Officer of Sanofi Genzyme. Marco Boorsma, General Partner at Forbion, who has acted as interim-CEO since company inception, will become a member of the Board.